European journal of clinical pharmacology · 2026
Mass balance study of [14C]-ABBV-552, a synaptic vesicle glycoprotein 2A positive modulator, in healthy male participants following single oral dose administration.
СтатьяКлиническое исследование I фазыНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miles Nick, McNamee Brian, Soleman Sharif I, Zadikoff Cindy, Boiser Joey, Laplanche Loic, Burton Richard, Shebley Mohamad, Boinpally Ramesh R
Аннотация
PURPOSE: Synaptic density is strongly correlated with cognitive function in many neurological disorders. All synapses contain synaptic vesicle glycoprotein 2 A (SV2A), making it a potential therapeutic target for neurodecline. ABBV-552, a high-affinity positive SV2A modulator, increases neurotransmitter release, improving synaptic efficiency. This Phase 1, open-label, mass balance study examined ABBV-552 safety, pharmacokinetics, metabolism, and elimination.
METHODS: Eight healthy males were orally administered 15 mg [14C]-ABBV-552. Safety was assessed via treatment-emergent adverse event (TEAE), vital sign, electrocardiogram, and laboratory value monitoring. Serial blood, urine, and fecal samples were collected pre-dose, Days 1-14, and daily until discharge. Sample radioactivity was measured with HPLC and metabolites characterized with mass spectrometry.
RESULTS: Eight participants (30-49 years old) received 15 mg [14C]-ABBV-552 (~ 100 µCi) and were included in analyses (3 prematurely withdrew [personal reasons]). All TEAEs were Grade 1 in severity; euphoria (25.0%), dizziness (25.0%), and muscular weakness (12.5%) were deemed possibly-related to ABBV-552. No meaningful changes in laboratory values, vital signs, or ECGs were observed. Mean radioactive recovery was 78.8% (urine: 70.9%, feces: 7.83%), with < 1% parent drug in excreta. Parent and one metabolite (M2, mono-oxidized parent) accounted for 84% and 13%, respectively, of circulating drug-related material. M5, M9, and M33 were most prominent in urine (~ 13%, ~ 17%, ~ 11% of dose, respectively); M2/M36 (coeluted; 1.4% of dose) in feces.
CONCLUSIONS: Orally-administered ABBV-552 was well absorbed and primarily recovered in urine as metabolites. M2 was the only major circulating metabolite. Therefore, ABBV-552 is primarily hepatically metabolized and metabolites are renally eliminated. These findings support further investigation of ABBV-552 in neurodegenerative disorders.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov (NCT06278766) Date of registration: 26 February 2024.
METHODS: Eight healthy males were orally administered 15 mg [14C]-ABBV-552. Safety was assessed via treatment-emergent adverse event (TEAE), vital sign, electrocardiogram, and laboratory value monitoring. Serial blood, urine, and fecal samples were collected pre-dose, Days 1-14, and daily until discharge. Sample radioactivity was measured with HPLC and metabolites characterized with mass spectrometry.
RESULTS: Eight participants (30-49 years old) received 15 mg [14C]-ABBV-552 (~ 100 µCi) and were included in analyses (3 prematurely withdrew [personal reasons]). All TEAEs were Grade 1 in severity; euphoria (25.0%), dizziness (25.0%), and muscular weakness (12.5%) were deemed possibly-related to ABBV-552. No meaningful changes in laboratory values, vital signs, or ECGs were observed. Mean radioactive recovery was 78.8% (urine: 70.9%, feces: 7.83%), with < 1% parent drug in excreta. Parent and one metabolite (M2, mono-oxidized parent) accounted for 84% and 13%, respectively, of circulating drug-related material. M5, M9, and M33 were most prominent in urine (~ 13%, ~ 17%, ~ 11% of dose, respectively); M2/M36 (coeluted; 1.4% of dose) in feces.
CONCLUSIONS: Orally-administered ABBV-552 was well absorbed and primarily recovered in urine as metabolites. M2 was the only major circulating metabolite. Therefore, ABBV-552 is primarily hepatically metabolized and metabolites are renally eliminated. These findings support further investigation of ABBV-552 in neurodegenerative disorders.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov (NCT06278766) Date of registration: 26 February 2024.